EP0594659A1 - Use of silicon compounds for preventing traumatic injuries - Google Patents
Use of silicon compounds for preventing traumatic injuriesInfo
- Publication number
- EP0594659A1 EP0594659A1 EP92914022A EP92914022A EP0594659A1 EP 0594659 A1 EP0594659 A1 EP 0594659A1 EP 92914022 A EP92914022 A EP 92914022A EP 92914022 A EP92914022 A EP 92914022A EP 0594659 A1 EP0594659 A1 EP 0594659A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- animal
- zeolite
- animals
- silicon compound
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to the prevention and reduction of susceptibility to traumatic injury by the administration of silicon compounds.
- silicate compounds have been reported to elevate blood, serum, plasma or urine levels of silicon when administered orally or by injection. These include sodium silicate, magnesium silicate, amorphous sodium aluminosilicate, and sodium zeolite A. Behnke and Osborn showed that sodium zeolite A was particularly effective in this regard. See Behnke, et al., Food. Cosm. Toxicol.. 17, 123-127, (1979).
- No.4,393,082 issued July 12, 1983 discloses the use of zeolites having exchangeable cations as a feed component in the feeding of urea or biuret non-protein nitrogen (NPN) compounds to ruminants, such as cattle, sheep and goats.
- NPN non-protein nitrogen
- Natural and synthetic as well as crystalline and non-crystalline zeolites are disclosed.
- Zeolites tested using in vitro techniques included natural zeolites, chabazite and clinoptilolite and synthetic zeolites X, Y, F, J, M, Z and A. Zeolite F was by far the most outstanding. Zeolite A was substantially ineffective.
- U.S. Pat. No. 4,847,085 discloses a method of improving the quality of the bones and/or increasing the bone strength of animals, including humans, cattle, sheep, goats, swine and poultry, without deleterious effects on the animals or products of the animals by adding a small, effective amount of zeolite to the feed of the animals or directly to the animals in the form of a capsule, tablet or the like.
- the spaces between the tetrahedra are occupied by water molecules prior to dehydration.
- zeolites There are a number of different types of zeolites. Some zeolites are found in nature and can also be made synthetically. Other zeolites are made only synthetically. Zeolite A is not found in nature and is made only synthetically.
- U.S. Pat. No. 4,847,085 discloses the nutritional uses of zeolites to strengthen bone. That patent references the variety and types of zeolites useful in the disclosed method and processes used to prepare such zeolites. It is an important object of this invention to provide a method for treating, preventing or delaying the effects of traumatic injury to the tissues of animals, including humans, by treatment of the animals with a relatively small amount of silicic acid produced by administering to the animal to be subjected to trauma- producing conditions metal silicates or aluminosilicates, especially zeolites. It is an object of the invention to provide an animal treatment or food containing zeolite, which inhibits the effects of traumatic injury in animals, especially humans.
- Another object of the invention is to provide a process for the treatment and/or prevention of the effects of traumatic injury to both hard and soft tissue in animals wherein an effective amount of zeolite is added to the diet of the animal.
- Still another object of the invention is to effectively treat, prevent or delay traumatic injury to the tissue of animals without causing any deleterious effects in the animals.
- Yet a further object of the present invention is to treat, prevent or delay the traumatic injury to the tissue of equine ammals.
- the present invention relates to a method of treating, preventing or delaying the traumatic injury to the tissue of animals, especially humans, by treating the animal with an effective amount of silicic acid produced by administering to the animal a silicon-containing compound.
- the silicic acid preferably is formed after administering to the animal to be subjected to trauma-causing conditions a physiologically acceptable silicon-containing compound that results in the formation (within the animal) of an effective amount of silicic acid.
- the silicon-containing compounds employed in this invention are those that are non-toxic and physiologically acceptable and, when administered to the animal, provide the animal with a source of silicic acid.
- the silicon-containing compounds can be entirely inorganic or organic silicon compounds.
- silicate esters are preferred and orthosilicates are particularly preferred, i.e., compounds of the formula Si(OR) 4 where R is an organic radical, such as to C 6 linear or branched alkyl (methyl, ethyl, or n-propyl). More than one type of R group may be combined.
- metal alumino- silicates are preferred. These include metals of Group IA, such as sodium or potassium, and metals of Group HA, such as calcium and magnesium. Examples of such compounds are potassium aluminosilicate, sodium aluminosilicate, calcium aluminosilicate and magnesium aluminosilicate.
- the zeolites, particularly zeolite A are included within such class of inorganic silicates.
- Administration may be by way of pellets, powder, tablets or capsules.
- Traumatic injury among race horses is well known to be a common occurrence.
- the following treatments were carried out.
- the silicic acid was generated within the animal by administering increasing levels of sodium zeolite A to a group of equines and subjecting them to a standardized regimen of training. It should be understood that the following examples are for the purpose of illustration only. They are not intended to limit this invention in any way.
- EXAMPLE 1 Starting at approximately six months of age, a group of Quarter Horses were administered a diet of concentrate and hay balanced to NRC guidelines [National Research Council (U.S.) (1989) Nutritional Requirements of Horses. National Academy Press, Washington, D.C.] supplemented with varying levels of sodium zeolite A(ZA). Animals were fed twice daily in individual stalls and otherwise allowed to exercise in a dry paddock. ZA constituted approximately 0, 0.66, 1.33, or 2.0 percent of their feed intake. Feed was composed of 75% concentrate and 25% coastal bermuda grass hay.
- the concentrate portion of the diet was composed of 87% pelleted concentrate (from corn, wheat mids, soybean meal, alfalfa meal, lignin binder, vitamin supplement, ground limestone and trace mineralized salt) and of 13% supplement of sodium zeolite A pelleted with dried alfalfa. Loading of 0, 6.6, 13.3 and 20% sodium zeolite A in the alfalfa pellets was used to allow constant volumes of supplement while varying the dose level of ZA. Feeding rates were increased as the animals grew so as to maintain approximately constant dosing on a body weight basis.
- mice were fed approximately 0.2% of their body weight as (zeolite A-containing) supplement each day as part of the concen-trate portion of their diet (including the 0 dose supplement).
- concentration of zeolite A in the supplement is from 6% to 20% by weight (this represents a dose of zeolite A of 0.12% to 0.4% as a fraction of the body weight).
- the treatments were labelled by drawing lots as A, B, D, C, respectively.
- Horses were randomly assigned to treatment, blocked by sex, weight and body condition score. Males were gelded at 1 year of age. After six months of treatment, animals, now approximately one year of age, were transferred to large forage- containing paddocks and fed again to NRC requirements with a combination of ad libitum hay and concentrate. Twice daily the horses were each provided 1.82 kg per head of concentrate feed (approximately 1% of body weight over a 180-day period). Animals were again provided with 0.2% of their body weight as the zeolite A-containing supplement (including the 0 dose supplement) in this concentrate. The ratio of supplement to the rest of the concentrate was increased to 20:80 to adjust for the changing nutritional requirements in horses of this age.
- mice were entered into a breaking/training/ racing program and conditioned to race from a starting gate. After 17 weeks of breaking and training (9 weeks of breaking and 8 weeks of combined long, slow distance and sprint conditioning and gate training), animals entered a racing program. Animals were raced on alternate weeks. During the week of the race, the following schedule was maintained: day 1 - warm up and gallop 1 mile; day 2 - walk 1 hour on the walker; day 3 - warm up, gallop 1/2 mile and sprint 150 yards; days 4 and 5 - walk; day 6 - race; day 7 - stall rest. Races were run at increasing distances as follows: races 1-3, 300 yards; races 4-6, 350 yards; races 7-9, 400 yards. Alternate weeks with no race the weekly schedule was: days 1 and 3 - warm up and gallop 1.5 miles; days 2, 4, 6 and 7 - walk; day 5 - warm up, gallop 1/2 mile and sprint 200 yards.
- the concentrate portion of the diet was composed of a 20:80 ratio of pelleted zeolite A-containing supplement to pelleted concentrate.
- the treatment regimen was maintained throughout the study. Trainers, jockeys, veterinarians and other personnel involved in handling, diagnosis and treatment were blinded as to the composition of the treatments.
- mice were assessed. They were defined to have been injured if as a result of training or racing at some point they were unable to perform at speed as a result of trauma induced by the galloping/sprinting activity. At this point, the beginning horses had completed eight races and the last entries had completed three races. Both soft and hard tissue injuries were counted. Percent injured within each group was assessed as was the distance and the number of strides to injury. One animal sustained an injury in an accident on the walker. It was not included in the analysis. Another animal was injured before entering the galloping/sprinting phase of the study, but recovered sufficiently to continue a normal training/racing activity. This animal was included in the analysis. Use of distance or strides run before first injury allowed comparison regardless of progress within the race schedule.
- Plasma silicon levels after 84 days of treatment were: P as a Si m
- the treatment leads to a dose related increase in the mean plasma level of silicon in treated horses.
- the increase of systemic silicon level is associated with the reduction of susceptibility to traumatic ° injury noted in Example 1.
- the usefulness of this invention is general. This is due to the common elements of traumatic injury, regardless of cause. Accordingly, the usefulness of this invention is not limited to athletic injury. Other applications include improved resistance to tissue damage in animals such as poultry, cattle, horses, pigs and humans during transportation, improved resistance to traumatic injury due to falls and so on.
Abstract
Procédé pour traiter, prévenir ou retarder une lésion traumatique occasionnée dans le tissu d'un animal, particulièrement chez l'homme, les équidés ou animaux analogues, comprenant le traitement dudit animal avec une quantité efficace d'acide silicique produite par ledit animal à partir d'un composé de silicium administré audit animal.A method for treating, preventing or delaying a traumatic lesion caused in the tissue of an animal, particularly in humans, equines or the like, comprising treating said animal with an effective amount of silicic acid produced by said animal from of a silicon compound administered to said animal.
Description
USE OF SILICON COMPOUNDS FOR PREVENTING TRAUMATIC INJURIES
Field of Invention
This invention relates to the prevention and reduction of susceptibility to traumatic injury by the administration of silicon compounds.
Background of Invention
While it has long been recognized that certain diseases such as those associated with genetic defects and dietary deficiency states, such as scurvy and rickets, lead to increased susceptibility to traumatic injury, the notion of administering a substance to a normally nourished and otherwise physically fit animal or person to reduce susceptibility to trauma is unusual.
A number of silicate compounds have been reported to elevate blood, serum, plasma or urine levels of silicon when administered orally or by injection. These include sodium silicate, magnesium silicate, amorphous sodium aluminosilicate, and sodium zeolite A. Behnke and Osborn showed that sodium zeolite A was particularly effective in this regard. See Behnke, et al., Food. Cosm. Toxicol.. 17, 123-127, (1979).
It is also well known that the form of silicon found in the blood is monosilicic acid [Si(OH)4], regardless of the source of silicon. See E. M. Carlisle, Silicon. 'Trace Elements in Human and Animal Nutrition". Vol.2, W. Merz, ed. Academic Press, Inc., Orlando, 1986, Ch. 7, pp. 373-390.
Over the years, a wide variety of experiments have been conducted throughout the world utilizing zeolites of many different types in the feeding of animals for varying reasons. Most of these experiments have been in animal nutrition or in increasing the production of food animals or their food products. Most of the animals fed zeolites have been poultry, cattle, sheep and swine. Zeolites fed to the animals were mainly naturally occurring or processed zeolites found in nature. Although some degree of success in some areas was achieved, most of the results were unfavorable.
C. Y. Chung, et al., Nongsa Sihom Youngu Pogo 1978, 20 (Livestock) pp. 77-83, has provided information on the effects of cation exchange capacity and particle size of zeolites on the growth, feed efficiency and feed materials utilizability
of broilers or broiling size chickens. Supplementing the feed of the broilers with naturally occurring zeolites, such as clinoptilolite, produces an increase in body weight gain. Chung et al. also reported that earlier results at the Livestock Experiment Station (1974, 1975, 1976 - Suweon, Korea) showed no significant difference when 1.5, 3, and 4.5 percent zeolite was added to chicken layer diets. Canadian Patent No.939,186 (U.S. Pat. No.4,393,082 issued July 12, 1983) discloses the use of zeolites having exchangeable cations as a feed component in the feeding of urea or biuret non-protein nitrogen (NPN) compounds to ruminants, such as cattle, sheep and goats. Natural and synthetic as well as crystalline and non-crystalline zeolites are disclosed. Zeolites tested using in vitro techniques included natural zeolites, chabazite and clinoptilolite and synthetic zeolites X, Y, F, J, M, Z and A. Zeolite F was by far the most outstanding. Zeolite A was substantially ineffective.
Experiments have been in progress in Japan since 1965 on the use of natural zeolite minerals as dietary supplements for poultry, swine and cattle. Significant increases in body weight per unit of feed consumed and in the general health of the animals has been reported (Minato, Hideo, Koatsugasu 6:536, 1968).
Reductions in malodor were also noted.
U.S. Pat. No. 4,847,085 discloses a method of improving the quality of the bones and/or increasing the bone strength of animals, including humans, cattle, sheep, goats, swine and poultry, without deleterious effects on the animals or products of the animals by adding a small, effective amount of zeolite to the feed of the animals or directly to the animals in the form of a capsule, tablet or the like. Zeolites consist basically of a three-dimensional framework of Si04 and A104 tetrahedra. The tetrahedra are cross-linked by the sharing of oxygen atoms so that the ratio of oxygen atoms to the total of the aluminum and silicon atoms is equal to two, i.e., 0/(Al+Si) =2. The electrovalence of each tetrahedra containing aluminum is balanced by the inclusion in the crystal of a cation, for example, a sodium ion. This balance may be expressed by the formula Al/Na= 1. The spaces between the tetrahedra are occupied by water molecules prior to dehydration. There are a number of different types of zeolites. Some zeolites are found in nature and can also be made synthetically. Other zeolites are made only
synthetically. Zeolite A is not found in nature and is made only synthetically.
As noted above, U.S. Pat. No. 4,847,085 discloses the nutritional uses of zeolites to strengthen bone. That patent references the variety and types of zeolites useful in the disclosed method and processes used to prepare such zeolites. It is an important object of this invention to provide a method for treating, preventing or delaying the effects of traumatic injury to the tissues of animals, including humans, by treatment of the animals with a relatively small amount of silicic acid produced by administering to the animal to be subjected to trauma- producing conditions metal silicates or aluminosilicates, especially zeolites. It is an object of the invention to provide an animal treatment or food containing zeolite, which inhibits the effects of traumatic injury in animals, especially humans.
Another object of the invention is to provide a process for the treatment and/or prevention of the effects of traumatic injury to both hard and soft tissue in animals wherein an effective amount of zeolite is added to the diet of the animal.
Still another object of the invention is to effectively treat, prevent or delay traumatic injury to the tissue of animals without causing any deleterious effects in the animals.
Yet a further object of the present invention is to treat, prevent or delay the traumatic injury to the tissue of equine ammals.
Other objects and advantages of the invention will be more fully understood from a reading of the description and claims hereinafter.
Summary of the Invention
The present invention relates to a method of treating, preventing or delaying the traumatic injury to the tissue of animals, especially humans, by treating the animal with an effective amount of silicic acid produced by administering to the animal a silicon-containing compound.
Description of the Preferred Embodiments
It has been discovered that by treating animals exposed to conditions known to generate both hard and soft tissue traumatic injury with silicic acid that such
injury is prevented or inhibited (delayed) from occurring. The silicic acid preferably is formed after administering to the animal to be subjected to trauma-causing conditions a physiologically acceptable silicon-containing compound that results in the formation (within the animal) of an effective amount of silicic acid. The silicon-containing compounds employed in this invention are those that are non-toxic and physiologically acceptable and, when administered to the animal, provide the animal with a source of silicic acid. Thus, the silicon-containing compounds can be entirely inorganic or organic silicon compounds. Concerning the latter, silicate esters are preferred and orthosilicates are particularly preferred, i.e., compounds of the formula Si(OR)4 where R is an organic radical, such as to C6 linear or branched alkyl (methyl, ethyl, or n-propyl). More than one type of R group may be combined. Concerning the former compounds, metal alumino- silicates are preferred. These include metals of Group IA, such as sodium or potassium, and metals of Group HA, such as calcium and magnesium. Examples of such compounds are potassium aluminosilicate, sodium aluminosilicate, calcium aluminosilicate and magnesium aluminosilicate. The zeolites, particularly zeolite A, are included within such class of inorganic silicates.
It has been found that by administering a small amount of silicon-containing compounds daily, sufficient silicic acid is produced that trauma-induced injury is prevented, inhibited or made less severe. When sodium zeolite A is used, 0.25% to 3.0% of the total food ingested by the animal is effective in this respect.
Administration may be by way of pellets, powder, tablets or capsules.
Traumatic injury among race horses is well known to be a common occurrence. In order to demonstrate the effectiveness of the method of this invention in preventing, inhibiting or treating the incidence of traumatic injury to the tissue of animals by treatment of such animals that have been subjected to conditions that have been shown to cause traumatic tissue injury, the following treatments were carried out. In the following examples, the silicic acid was generated within the animal by administering increasing levels of sodium zeolite A to a group of equines and subjecting them to a standardized regimen of training. It should be understood that the following examples are for the purpose of illustration only. They are not intended to limit this invention in any way.
EXAMPLE 1 Starting at approximately six months of age, a group of Quarter Horses were administered a diet of concentrate and hay balanced to NRC guidelines [National Research Council (U.S.) (1989) Nutritional Requirements of Horses. National Academy Press, Washington, D.C.] supplemented with varying levels of sodium zeolite A(ZA). Animals were fed twice daily in individual stalls and otherwise allowed to exercise in a dry paddock. ZA constituted approximately 0, 0.66, 1.33, or 2.0 percent of their feed intake. Feed was composed of 75% concentrate and 25% coastal bermuda grass hay. The concentrate portion of the diet was composed of 87% pelleted concentrate (from corn, wheat mids, soybean meal, alfalfa meal, lignin binder, vitamin supplement, ground limestone and trace mineralized salt) and of 13% supplement of sodium zeolite A pelleted with dried alfalfa. Loading of 0, 6.6, 13.3 and 20% sodium zeolite A in the alfalfa pellets was used to allow constant volumes of supplement while varying the dose level of ZA. Feeding rates were increased as the animals grew so as to maintain approximately constant dosing on a body weight basis. Thus, animals were fed approximately 0.2% of their body weight as (zeolite A-containing) supplement each day as part of the concen-trate portion of their diet (including the 0 dose supplement). The concentration of zeolite A in the supplement is from 6% to 20% by weight (this represents a dose of zeolite A of 0.12% to 0.4% as a fraction of the body weight).
To maintain blinding, the treatments were labelled by drawing lots as A, B, D, C, respectively. Horses were randomly assigned to treatment, blocked by sex, weight and body condition score. Males were gelded at 1 year of age. After six months of treatment, animals, now approximately one year of age, were transferred to large forage- containing paddocks and fed again to NRC requirements with a combination of ad libitum hay and concentrate. Twice daily the horses were each provided 1.82 kg per head of concentrate feed (approximately 1% of body weight over a 180-day period). Animals were again provided with 0.2% of their body weight as the zeolite A-containing supplement (including the 0 dose supplement) in this concentrate. The ratio of supplement to the rest of the concentrate was increased to 20:80 to adjust for the changing nutritional
requirements in horses of this age.
At the end of the intermediate six-month paddock feeding phase, animals were entered into a breaking/training/ racing program and conditioned to race from a starting gate. After 17 weeks of breaking and training (9 weeks of breaking and 8 weeks of combined long, slow distance and sprint conditioning and gate training), animals entered a racing program. Animals were raced on alternate weeks. During the week of the race, the following schedule was maintained: day 1 - warm up and gallop 1 mile; day 2 - walk 1 hour on the walker; day 3 - warm up, gallop 1/2 mile and sprint 150 yards; days 4 and 5 - walk; day 6 - race; day 7 - stall rest. Races were run at increasing distances as follows: races 1-3, 300 yards; races 4-6, 350 yards; races 7-9, 400 yards. Alternate weeks with no race the weekly schedule was: days 1 and 3 - warm up and gallop 1.5 miles; days 2, 4, 6 and 7 - walk; day 5 - warm up, gallop 1/2 mile and sprint 200 yards.
During this stage of treatment, horses were maintained in individual stalls and fed every 12 hours. The animals were fed a ratio of concentrate to hay of 70:30 sufficient to maintain their body condition. As in the previous stage, the concentrate portion of the diet was composed of a 20:80 ratio of pelleted zeolite A-containing supplement to pelleted concentrate.
The treatment regimen was maintained throughout the study. Trainers, jockeys, veterinarians and other personnel involved in handling, diagnosis and treatment were blinded as to the composition of the treatments.
Beginning on February 7, over a three-month period ending March 29, six groups of animals began their first race, according to their age. Animals were evaluated for injury sustained as a result of trauma induced by the sprinting/ galloping activity of their conditioning and racing.
On May 28, animals were assessed. They were defined to have been injured if as a result of training or racing at some point they were unable to perform at speed as a result of trauma induced by the galloping/sprinting activity. At this point, the beginning horses had completed eight races and the last entries had completed three races. Both soft and hard tissue injuries were counted. Percent injured within each group was assessed as was the distance and the number of strides to injury. One animal sustained an injury in an accident on the walker.
It was not included in the analysis. Another animal was injured before entering the galloping/sprinting phase of the study, but recovered sufficiently to continue a normal training/racing activity. This animal was included in the analysis. Use of distance or strides run before first injury allowed comparison regardless of progress within the race schedule.
The incidence of injury versus dose level of ZA in the supplement and the mean distance run before first injury in strides and yards were as follows:
Distance to
Dose (%ZA) Percent Injured 1st Injury - Strides/Yards
0.0 62 8537/41151 6.66 36 13665/65005 13.3 33 15380/71358 20.0 27 14901/68534
Injuries were classified by treatment and number of ammals per group (N) as follows:
Treatment (%ZA)/(N) Injuries 0.0/(13) Fractured Sesamoid
Swollen Hind Leg
Bone Sprain
Sesamoiditis/Possible Fracture
Tied Up
Swollen Hind Legs
Intermittent Lameness in Left Front Leg
6.66/(14) Shin Bucked
Hind End Lameness
Shin Bucked
Shin Bucked
Shin Bucked
13.3/(9) Knee Chip/Fractured Sesamoid/ Arthritis Hairline Fracture of Carpal Bone Fractured Distal Cannon
20.0/(11) Possible Knee Chip Bowed Tendon Bowed Tendon
Data were collected for horses injured during conditioning or racing. To assess similar situations, only horses injured under the controlled stress of galloping or sprinting were analyzed. Horses were disqualified from the analysis if they were injured due to accidents not associated with athletic events or incapacitated prior to entry into the training/racing phase. Disqualifications were evenly distributed across treatments and due to the following causes not related to treatment:
1) Lame right front leg. (Occurred during breaking.) 1 horse - Treatment D.
2) Physitis related to conformation (genetic origin - same sire). 1 each - Treatment B and C.
3) Osteochondrosis. (Present upon arrival.) Treatment D.
4) Fractures - chipped knee, sesamoid. (Occurred during breaking.) 1 each - Treatments A and D.
Clearly, treatment led to reduction in both hard and soft tissue injuries in a dose related manner.
EXAMPLE 2
Blood was drawn from horses at intervals throughout the study and analyzed for its silicon content. The method of Gitelman and Alderman was used to determine the level of silicon in the plasma. Gitelman, H.J. and Alderman, F.R., 1991, "Determination of silicon in biological samples using electrothermal atomic absorption spectrometry", J. Analytical Atomic Spectrometry. 5:687. Zeolite A treatment was seen to increase the plasma silicon level in a dose dependent manner.
Samples were taken just prior to feeding (T=0), and at 1, 3, 6 and 9 hours after feeding. The mean of the evenly spaced samples at 0, 3, 6 and 9 hours was used to calculate the mean plasma silicon level.
Plasma silicon levels after 84 days of treatment were:
P as a Si m
As can be seen from the Example, the treatment leads to a dose related increase in the mean plasma level of silicon in treated horses. The increase of systemic silicon level is associated with the reduction of susceptibility to traumatic ° injury noted in Example 1.
It will be recognized by those skilled in the art that the usefulness of this invention is general. This is due to the common elements of traumatic injury, regardless of cause. Accordingly, the usefulness of this invention is not limited to athletic injury. Other applications include improved resistance to tissue damage in animals such as poultry, cattle, horses, pigs and humans during transportation, improved resistance to traumatic injury due to falls and so on.
Claims
1. A method for the prevention or delay of hard or soft tissue physical trauma in an animal, comprising treating said animal with an effective amount of silicic acid produced by said animal from a silicon compound administered to said animal.
2. The method according to Claim 1 wherein said tissue is hard tissue.
3. The method according to Claim 1 wherein said tissue is soft tissue.
4. The method according to Claim 1 wherein said silicon compound is an organic silicon compound.
5. The method according to Claim 1 wherein said silicon compound is an inorganic silicon compound.
6. The method according to Claim 5 wherein said silicon compound is zeolite.
7. The method according to Claim 5 wherein said zeolite is zeolite A.
8. A method for the prevention or delay of hard or soft tissue physical trauma in an animal, comprising treating said animal with an effective amount of silicic acid produced by said animal from zeolite A administered to said animal.
9. The method according to Claim 8 wherein said animal being treated s a human being.
10. The method according to Claim 8 wherein said animal being treated s equine, bovine, canine, feline, swine or poultry.
11. The method according to Claim lOwherein said animal is equine.
12. A method for the prevention or delay of hard or soft tissue physical trauma in a human being, comprising treating said human being with an effective amount of silicic acid produced by said human being from zeolite A administered to said human being at about 0.25 to about 3.00 weight percent of the daily food intake of said human being.
13. The method according to Claim 12 wherein the amount administered is from 0.12 to 0.4 percent of body weight.
14. The method according to Claim 12 wherein said zeolite A is administered in tablet, pelleted, powdered or capsule form.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73008591A | 1991-07-15 | 1991-07-15 | |
| US730085 | 1991-07-15 | ||
| PCT/US1992/005179 WO1993001819A1 (en) | 1991-07-15 | 1992-06-16 | Use of silicon compounds for preventing traumatic injuries |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0594659A1 true EP0594659A1 (en) | 1994-05-04 |
Family
ID=24933845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP92914022A Withdrawn EP0594659A1 (en) | 1991-07-15 | 1992-06-16 | Use of silicon compounds for preventing traumatic injuries |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0594659A1 (en) |
| JP (1) | JPH06509103A (en) |
| CA (1) | CA2111972A1 (en) |
| WO (1) | WO1993001819A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05005286A (en) * | 2002-11-18 | 2006-02-22 | Grenpharma Llc | Compositions for treating and/or preventing diseases characterized by the presence of metal ions. |
| CN1245220C (en) * | 2003-04-09 | 2006-03-15 | 江苏阳生生物工程有限公司 | New dressing matorial for promoting quick repair of surface of dermal wound |
| US8883194B2 (en) | 2007-11-09 | 2014-11-11 | Honeywell International, Inc. | Adsorbent-containing hemostatic devices |
| US8795718B2 (en) | 2008-05-22 | 2014-08-05 | Honeywell International, Inc. | Functional nano-layered hemostatic material/device |
| JP5926282B2 (en) * | 2010-12-16 | 2016-05-25 | タフロック テクノロジー プロプライアタリー リミテッド | Improved mineral compositions and methods of use |
| WO2023012147A1 (en) | 2021-08-03 | 2023-02-09 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4556564A (en) * | 1983-03-14 | 1985-12-03 | Ethyl Corporation | Feeding of zeolite A to poultry |
| US5082662A (en) * | 1983-03-14 | 1992-01-21 | Ethyl Corporation | Bone disorder treatment |
| DE68909229T2 (en) * | 1988-02-08 | 1994-01-27 | Ethyl Corp | ZEOLITE PREPARATIONS. |
| EP0425565B1 (en) * | 1988-07-22 | 1994-09-21 | Ethyl Corporation | Silicon compounds in bone treatment |
| US4870191A (en) * | 1988-07-22 | 1989-09-26 | Ethyl Corporation | Silicon containing reaction product |
| FI94715C (en) * | 1991-01-28 | 1995-10-25 | Steel Joint Ltd Oy | Mixture used as an additive in animal nutrition, to promote animal growth and to strengthen bones and tissues |
-
1992
- 1992-06-16 EP EP92914022A patent/EP0594659A1/en not_active Withdrawn
- 1992-06-16 WO PCT/US1992/005179 patent/WO1993001819A1/en not_active Application Discontinuation
- 1992-06-16 JP JP5502466A patent/JPH06509103A/en active Pending
- 1992-06-16 CA CA002111972A patent/CA2111972A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO9301819A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2111972A1 (en) | 1993-02-04 |
| JPH06509103A (en) | 1994-10-13 |
| WO1993001819A1 (en) | 1993-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6524609B1 (en) | Treating arthritis in animals with dietary supplements | |
| CA2671747C (en) | Animal feed compositions | |
| Nielsen et al. | Training distance to failure in young racing quarter horses fed sodium zeolite A | |
| EP0594659A1 (en) | Use of silicon compounds for preventing traumatic injuries | |
| McDowell et al. | Selenium availability and methods of selenium supplementation for grazing ruminants | |
| Nielsen et al. | A marine mineral supplement alters markers of bone metabolism in yearling arabians | |
| CA2996879C (en) | Methods and formulations for reducing ammonia emissions from bovines | |
| US20120328715A1 (en) | Prevention and treatment of osteochondrosis in animals and humans | |
| Harris et al. | Effect of exercise and diet on the incidence of DOD | |
| Rezende et al. | Effect of two different nutritional programs on orthopedic alterations in Mangalarga Marchador foals | |
| JP2008541767A5 (en) | ||
| Hildebran et al. | Copper-responsive epiphysitis and tendon contracture in a foal | |
| Hooper et al. | The prevention and treatment of Birdsville disease of horses | |
| El-Hawy et al. | Effect of Zeolite Addition on Physiological, Immunological, Reproductive and Productive Performance of Barki Ewes Under Water Salinity Stress in South Sinai, Egypt | |
| NL2007581C2 (en) | Method for preventing osteochondrosis. | |
| Olson | Effect of Sunlight on the Growth, Production and Reproductiion of Dairy Cattle | |
| RU2435436C2 (en) | Feed composition for prevention or therapy of animal adiposity, method for prevention or therapy of animal adiposity, composition for self-regulation of feed product consumption by animal, method for self-regulation of feed product consumption by animal, set, application of capsaicionid for feed compositions production | |
| Peiper et al. | Zeolite Studies | |
| EP2035019A1 (en) | Prevention and treatment of osteochondrosis in animals and humans | |
| JPS63502835A (en) | Immune modulators that improve commercial performance in livestock |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19940110 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): DE FR GB IT |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ALBEMARLE CORPORATION |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ALBEMARLE CORPORATION |
|
| 17Q | First examination report despatched |
Effective date: 19951208 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Withdrawal date: 19960412 |